CStone Pharmaceuticals 2616
HKEX · Hong Kong SAR China · Health Technology
HKD 5.66-0.25 (-4.15%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue | HKD 300.32M | HKD 432.40M | HKD 516.25M | HKD 546.22M |
| Revenue growth (YoY) | -30.5% | -16.2% | -5.5% | — |
| Cost of Revenue | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Gross Profit | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Gross margin | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating expenses | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating Income | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating margin | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| EBITDA | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Pre-tax income | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Income tax | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Net Income | -HKD 486.83M | -HKD 96.85M | -HKD 408.73M | -HKD 1.02B |
| Net margin | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted EPS | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted shares | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Cash & equivalents | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Current Assets | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Assets | HKD 1.51B | HKD 1.48B | HKD 1.85B | HKD 1.86B |
| Total Current Liabilities | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Liabilities | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total debt | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Equity | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Cash from Operations | -HKD 365.11M | -HKD 321.98M | -HKD 655.38M | -HKD 693.03M |
| Capital expenditure | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Free cash flow | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Investing | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Financing | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
Standardised statements compiled from the company's annual and interim reports. The "LTM" column covers the last four reported quarters; balance-sheet lines in it are from the latest quarter. Lines the company does not report are left blank rather than approximated. Not investment advice. The company reports in CNY; every figure is converted to HKD at the exchange rate of its own period end (the latest rate for LTM), so it can be compared with the share price.